Relmada Therapeutics (NASDAQ:RLMD) reported Q4 EPS of ($1.80), $0.03 better than the analyst estimate of ($1.83).
For earnings history and earnings-related data on Relmada Therapeutics (RLMD) click here.
Relmada Therapeutics (NASDAQ:RLMD) reported Q4 EPS of ($1.80), $0.03 better than the analyst estimate of ($1.83).
For earnings history and earnings-related data on Relmada Therapeutics (RLMD) click here.